Medocef

Cefoperazone sodium, the active ingredient in Medocef, is a third‑generation cephalosporin presented as an injectable solution for intramuscular and intravenous use. It treats severe bacterial infections, including respiratory, urinary, intra‑abdominal, and skin‑soft tissue infections, in hospitalized patients.

GNH USA supplies Medocef as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, clinics and other healthcare facilities worldwide. The company adheres to EU GMP standards and provides full batch documentation for traceability through reliable logistics networks and timely delivery.

Cefoperazone sodium is a broad‑spectrum third‑generation cephalosporin used to treat serious bacterial infections affecting various organ systems.

- Respiratory tract infections: effective against severe pneumonia and bronchitis caused by susceptible bacteria. - Urinary tract infections: clears complicated UTIs caused by Gram‑negative organisms. - Intra‑abdominal infections: treats peritonitis and intra‑abdominal sepsis. - Skin and soft‑tissue infections: resolves cellulitis and wound infections. - Severe bacterial infections: used for systemic infections where broad coverage is required.

Cefoperazone sodium may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Diarrhea: mild to moderate loose stools. - Nausea: occasional feeling of queasiness. - Vomiting: intermittent emesis. - Rash: erythematous skin eruptions. - Injection site pain: local discomfort after IM/IV administration. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Clostridioides difficile‑associated colitis: severe watery diarrhea. - Anaphylaxis: acute hypersensitivity with respiratory distress. - Stevens‑Johnson syndrome: severe mucocutaneous reaction. - Hemolytic anemia: destruction of red blood cells. - Renal impairment: worsening kidney function. - Thrombocytopenia: reduced platelet count leading to bleeding.

When using Cefoperazone sodium, clinicians should consider several safety aspects.

- Renal function: adjust dose in patients with impaired kidney function. - Hepatic impairment: monitor liver enzymes in patients with liver disease. - Beta‑lactam allergy: avoid in individuals with known hypersensitivity to cephalosporins or penicillins. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited. - Elderly patients: start with lower doses and monitor for adverse effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Cefoperazone sodium can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Probenecid: may increase cefoperazone plasma concentrations, raising toxicity risk. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Live vaccines: concurrent use may reduce vaccine efficacy and increase infection risk.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxicity; monitor renal function. - Diuretics: may enhance electrolyte disturbances. - Oral contraceptives: possible reduction in contraceptive efficacy; advise alternative methods. - Other antibiotics: overlapping spectra may increase risk of superinfection.